Advanced age is an independent prognostic factor of disease progression in high-risk prostate cancer: results in 180 patients treated with robot-assisted radical prostatectomy and extended pelvic lymph node dissection in a tertiary referral center

Author:

Porcaro Antonio Benito,Bianchi Alberto,Gallina Sebastian,Panunzio Andrea,Serafin Emanuele,Mazzucato Giovanni,Orlando Rossella,Montanaro Francesca,Patuzzo Giulia Marafioti,Baielli Alberto,Artoni Francesco,Ditonno Francesco,Vidiri Stefano,D’Aietti Damiano,Migliorini Filippo,Rizzetto Riccardo,Veccia Alessandro,Gozzo Alessandra,Brunelli Matteo,Tafuri Alessandro,Cerruto Maria Angela,Antonelli Alessandro

Abstract

Abstract Objectives This study aimed to assess more clinical and pathological factors associated with prostate cancer (PCa) progression in high-risk PCa patients treated primarily with robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND) in a tertiary referral center. Materials and methods In a period ranging from January 2013 to October 2020, RARP and ePLND were performed on 180 high-risk patients at Azienda Ospedaliera Universitaria Integrata of Verona (Italy). PCa progression was defined as biochemical recurrence/persistence and/or local recurrence and/or distant metastases. Statistical methods evaluated study endpoints, including Cox’s proportional hazards, Kaplan-Meyer survival curves, and binomial logistic regression models. Results The median age of included patients was 66.5 [62–71] years. Disease progression occurred in 55 patients (30.6%), who were more likely to have advanced age, palpable tumors, and unfavorable pathologic features, including high tumor grade, stage, and pelvic lymph node invasion (PLNI). On multivariate analysis, PCa progression was predicted by advanced age (≥ 70 years) (HR = 2.183; 95% CI = 1.089–4377, p = 0.028), palpable tumors (HR = 3.113; 95% CI = 1.499–6.465), p = 0.002), and PLNI (HR = 2.945; 95% CI = 1.441–6.018, p = 0.003), which were associated with clinical standard factors defining high-risk PCa. Age had a negative prognostic impact on elderly patients, who were less likely to have palpable tumors but more likely to have high-grade tumors. Conclusions High-risk PCa progression was independently predicted by advanced age, palpable tumors, and PLNI, which is associated with standard clinical prognostic factors. Consequently, with increasing age, the prognosis is worse in elderly patients, who represent an unfavorable age group that needs extensive counseling for appropriate and personalized management decisions.

Funder

Università degli Studi di Verona

Publisher

Springer Science and Business Media LLC

Subject

Geriatrics and Gerontology,Aging

Reference19 articles.

1. Mottet N, Cornford P, van den Bergh RCN, et al (2022) EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. In: European Association of Urology. https://uroweb.org/guidelines/prostate-cancer. Accessed 27 Jan 2023

2. Schaeffer E, Srinivas S, An Y, et al (2022) Prostate Cancer, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. In: National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 27 Jan 2023

3. Artibani W, Porcaro AB, De Marco V et al (2018) Management of biochemical recurrence after primary curative treatment for prostate cancer: a review. Urol Int 100:251–262. https://doi.org/10.1159/000481438

4. Wallis CJD, Zhao Z, Huang L-C et al (2022) Association of treatment modality, functional outcomes, and baseline characteristics with treatment-related regret among men with localized prostate cancer. JAMA Oncol 8:50. https://doi.org/10.1001/jamaoncol.2021.5160

5. Dripps RD (1961) The role of anesthesia in surgical mortality. JAMA 178:261. https://doi.org/10.1001/jama.1961.03040420001001

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3